Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Other Working Capital Changes (2017 - 2025)

Historic Other Working Capital Changes for Cue Biopharma (CUE) over the last 9 years, with Q3 2025 value amounting to $3.9 million.

  • Cue Biopharma's Other Working Capital Changes rose 58663.3% to $3.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 million, marking a year-over-year increase of 18674.58%. This contributed to the annual value of -$2.0 million for FY2024, which is 2873.03% up from last year.
  • According to the latest figures from Q3 2025, Cue Biopharma's Other Working Capital Changes is $3.9 million, which was up 58663.3% from -$2.6 million recorded in Q2 2025.
  • In the past 5 years, Cue Biopharma's Other Working Capital Changes ranged from a high of $6.4 million in Q4 2021 and a low of -$6.3 million during Q3 2021
  • For the 5-year period, Cue Biopharma's Other Working Capital Changes averaged around $126227.5, with its median value being $161750.0 (2022).
  • Its Other Working Capital Changes has fluctuated over the past 5 years, first tumbled by 263913.04% in 2021, then surged by 58663.3% in 2025.
  • Cue Biopharma's Other Working Capital Changes (Quarter) stood at $6.4 million in 2021, then crashed by 124.63% to -$1.6 million in 2022, then surged by 54.21% to -$724000.0 in 2023, then surged by 144.48% to $322000.0 in 2024, then skyrocketed by 1098.45% to $3.9 million in 2025.
  • Its last three reported values are $3.9 million in Q3 2025, -$2.6 million for Q2 2025, and $1.1 million during Q1 2025.